
    
      This is a single-center, open-label, non-randomized, prospective phase II trial. Sutent
      treatment will be continued until disease progression, or excessive toxicity (as determined
      by treating physician or primary investigator), or until a maximum of eight cycles, whichever
      duration is shorter.
    
  